Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (151-160 of 265) with videos related to

Pageof 27
Sort By:
The Journal of Investigative Dermatology|July 26, 2021
Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis VulgarisAlexandros Onoufriadis, Umar Niazi, Konstantina Dimitrakopoulou, et al.
Dermatology and Therapy|January 6, 2022
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
BMJ Open|September 14, 2021
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|July 4, 2018
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 studyCarle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, et al.
Arthritis and Rheumatism|July 9, 2003
Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritisSabine Blaschke, Peter Middel, Brigitte G Dorner, et al.
Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
Dermatology and Therapy|September 26, 2023
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2Byung Soo Kim, Seong Jin Jo, SangWoong Youn, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Pageof 27

Showing results (151-160 of 265) with videos related to

Sort By:
Pageof 27
The Journal of Investigative Dermatology|July 26, 2021
Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis VulgarisAlexandros Onoufriadis, Umar Niazi, Konstantina Dimitrakopoulou, et al.
Dermatology and Therapy|January 6, 2022
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
BMJ Open|September 14, 2021
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)Kilian Eyerich, Peter Weisenseel, Andreas Pinter, et al.
Journal of the American Academy of Dermatology|July 4, 2018
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 studyCarle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, et al.
Arthritis and Rheumatism|July 9, 2003
Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritisSabine Blaschke, Peter Middel, Brigitte G Dorner, et al.
Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
Dermatology and Therapy|September 26, 2023
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2Byung Soo Kim, Seong Jin Jo, SangWoong Youn, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Pageof 27